Kinfo
Lineage Cell Therapeutics, Inc. logo

Lineage Cell Therapeutics, Inc.

LCTXNYSEHealthcare·US · USD
$0.99
-0.04 (-3.88%)
Prices as of October 9, 2026 · market closed

Price

Key statistics

Valuation
Market cap260.49M USD
Enterprise value210.85M USD
Trailing P/E-3.59
Forward P/E-7.49
PEG ratio0.03
Price / sales19.91
Price / book4.27
Profitability
Gross margin100.00%
Operating margin-834.70%
Profit margin-246.58%
Return on assets-17.04%
Return on equity-60.06%
Income (TTM)
Revenue13.08M USD
Gross profit-7.50M USD
EBITDA27.36M USD
Net income-32.26M USD
Diluted EPS-$0.19
Rev. growth (YoY)-61.30%
Balance sheet
Total cash50.83M USD
Total debt2.30M USD
Debt / equity3.85
Current ratio6.61
Book value / share$0.24
Cash flow (TTM)
Operating cash flow-23.82M USD
Levered free cash flow-14.77M USD
Shares & price
Shares outstanding252.91M
Float190.90M
Held by institutions48.22%
Beta1.60
50-day MA$1.05
200-day MA$1.39
52-week high$2.09
52-week low$0.88
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Recent payments
  • 2003-12-15$0.06
Earnings (EPS)
DateEst.ActualSurprise2026-08-06-0.030.01+133.33%2026-05-262.343.14+34.19%2026-01-281.031.03+0.00%2025-11-06-0.03-0.13−333.33%
About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, or off-the-shelf, cell therapies for serious medical conditions. Its current programs center on cell replacement therapies for ophthalmology, neurology, hearing loss, and corneal disease, with product candidates designed to restore or replace damaged cells in targeted tissues. The company’s pipeline includes OpRegen for retinal disorders, OPC1 for spinal cord injury, COR1 for corneal endothelial disease, and other platform-based programs supported by its proprietary manufacturing and delivery capabilities. Lineage Cell Therapeutics, Inc. works at the intersection of regenerative medicine and specialty therapeutics, addressing areas of high unmet medical need through pluripotent stem cell-based technologies.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Brian M. Culley M.A., M.B.A.
Employees
72
Headquarters
Carlsbad, CA, United States

Frequently asked questions about Lineage Cell Therapeutics, Inc.